Subjects completing the HMR 1726D/2001 study are given the opportunity to continue or switch to teriflunomide for 528 weeks or until teriflunomide is commercially available in the country where patient lives;~subjects on Teriflunomide 7 mg or 14 mg continue on the same dose of teriflunomide.~subjects on placebo are randomized to teriflunomide 7 mg or 14 mg.~The total study period per subject is 532 weeks or until teriflunomide is commercially available in the country where patient lives, broken up as follows:~Treatment: 528 weeks or until teriflunomide is commercially available in the country where patient lives,~Post-washout follow-up: 4 weeks after last treatment intake.
The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.